Apo E, a key regulator of cholesterol-rich lipoprotein metabolism, is synthesized by numerous extrahepatic tissues. Although its synthesis in macrophages is documented, the contribution of macrophage-derived apo E to hepatic clearance of serum cholesterol is unknown. To address this issue bone marrow transplantation was performed on hypercholesterolemic apo E-deficient mice with either syngeneic apo Edeficient mouse bone marrow cells (EO-control) or wildtype mouse bone marrow cells expressing apo E (EOtreated). EO-control and EO-treated mice were fed either a regular chow diet or an atherogenic diet (designated EOcontrol-HF and EO-treated-HF). Serum cholesterol levels dropped dramatically in the EO-treated mice largely due to a reduction in their VLDL cholesterol. No changes were seen in the EO-control mice. After 4 wk serum cholesterol in EO-treated-HF mice was about four-fold lower compared to EO-control-HF animals. Moreover, the extent of atherosclerosis in the EO-treated-HF mice after 14-16 wk was greatly reduced. Wild-type apo E mRNA was detected in the liver, spleen, and brain of the EO-treated mice indicating that apo E gene transfer was successfully achieved through bone marrow transplantation. More importantly, the level of apo E expression was sufficient to reduce the severe hypercholesterolemia of the apo E-deficient mice fed either chow or atherogenic diets. (J. Clin. Invest. 1995. 96:1118-1124
Introduction
Apo E is a constituent of cholesterol-rich plasma lipoproteins including hepatically derived VLDL lipoproteins to hepatic LDL receptors (LDL-R)' and the LDL-R-related protein (LRP) , thereby directing these lipoproteins to the only organ that can facilitate their removal from the body.
Although the liver is a major site of apo E synthesis, other tissues including brain, spleen, adrenal gland, lung, testis, and ovary synthesize this protein (1) (2) (3) . Apo E is synthesized by monocyte/macrophages (4, 5) , but not by leukocytes (including lymphocytes and granulocytes) depleted of monocyte/macrophages (1) . In tissues, apo E is detected in the cytoplasm of all tissue macrophages (including Kupffer cells, histiocytes, and lymph node macrophages) but not in other immune cells such as lymphoid cells of spleen and lymph nodes (6) . Macrophage-derived apo E is postulated to be involved in immunoregulation (7) , regeneration of peripheral nerves (8) , and prevention of cholesteryl ester accumulation (9, 10). However, the contribution of macrophage apo E to hepatic removal of cholesterol-rich lipoproteins has been considered minimal. For example, it was estimated in liver transplant patients that extrahepatically derived apo E contributes < 10% to plasma levels of apo E ( 11) .
Two groups of investigators independently reported the creation of apo E-deficient mice by gene targeting in embryonic stem cells (12, 13) . These mice display severe hypercholesterolemia even on a low fat, low cholesterol chow diet. Fast protein liquid chromatography (FPLC) profiles of their plasma demonstrate elevated levels of cholesterol in VLDL, intermediate density lipoprotein (IDL) and, to a lesser degree, LDL. This is accompanied by a lower HDL cholesterol (12, 13) . This lipoprotein phenotype is even more pronounced when the mice are fed an atherogenic diet. Furthermore, in contrast to wild-type mice, which are resistant to atherosclerosis, apo E-deficient mice develop the early fatty streak lesions of atherosclerosis within a few months of birth (12, 13).
There are differences in lipoprotein metabolism between humans and mice. In humans, apo B is a ligand for the LDL-R along with apo E, albeit with lower affinity than apo E. This hepatic apo B is secreted as a full length protein (apo B100) that contains the LDL-R-binding domain. In mice a large portion of the hepatically derived apo B is truncated (apo B48) and does not contain the LDL-R-binding domain. Whereas wild-type mouse VLDL and IDL contain equal proportions of apo B48 and apo B100, VLDL and IDL from apo E-deficient mice contain -20-fold higher apo B48 than apo B100 (13) . This increase reflects the impaired apo E-dependent clearance of these VLDL remnants. With such a compromised compensatory mechanism for hepatic clearance of VLDL and IDL due to the low levels of apo B 100, apo E is requisite in mice for catabolizing these lipoproteins. This is evidenced by the severe hypercholesterolemia with accumulation of VLDL and IDL cholesterol seen in apo E-deficient mice. Additionally, LRP binds apo E but not apo B (14) , thereby compromising the LRP-mediated hepatic cholesterol clearance in these apo E-deficient mice as well.
By transplanting wild-type bone marrow cells into irradiated apo E-deficient mice, we created mice whose sole source of apo E was bone marrow-derived macrophages. These mice served as models to study the contribution of macrophage-derived apo E to the hepatic clearance of cholesterol. Our findings indicate that bone marrow transplantation after total body irradiation successfully transferred the apo E gene into the apo E-deficient mice and that apo E resulting from the transplanted normal bone marrow-derived macrophages reversed the hypercholesterolemia normally seen in these apo E-deficient mice when they were fed a chow diet. On an atherogenic diet both the severe hypercholesterolemia and the extent of atherosclerosis in the apo E-deficient mice were drastically reduced by transplantation of wild-type bone marrow.
Methods
Animals. C57BL/6J apo E-deficient mice were obtained from The Jackson Laboratories (Bar Harbor, ME Preparation and examination ofaortaefor atherosclerosis. To qualitatively assess the extent of atherosclerosis throughout the entire length of the aorta from the aortic valve to the iliac bifurcation, EO-control-HF and EO-treated-HF mice were killed 14-16 wk after bone marrow transplantation. The tissues were prepared as described (16) . Briefly, the blood was removed by perfusion with PBS (pH 7.4) into the left ventricle via a cannula. An incision was made in the inferior vena cava to clear the perfusate. The tissues were fixed by continued perfusion with formal-sucrose (4% paraformaldehyde and 5% sucrose, pH 7.4). The aortae were revealed by microscopic dissection, their adventitia cleaned and while attached, opened longitudinally from the common iliac arteries to the aortic valve. Then the aortae were detached and pinned flat onto the smooth black wax surface of a dissecting pan with 0.2-mm diameter stainless steel pins before they were stained with Sudan IV. Stained fatty streak lesions appeared bright red.
Statistics. Student's t test was performed on the serum cholesterol data between the EO-control-HF and EO-treated-HF mice. The results are given as mean+standard deviation. Sigma Plot (version 2.0; Jandel Corp., San Rafael, CA) was used for data analysis. 
Results
Micefed standard chow diet. The six chow-fed apo E-deficient mice shown in Fig. 1 were from the same litter. They had similar total serum cholesterol levels before irradiation and bone marrow transplantation (range: 221-331 mg/dl; mean±SD 275±39 mg/dl). By 4 wk, serum cholesterol dropped in the EO-treated mice (mean±SD 100±8 mg/dl), while it remained high in the EO-control mice (295 and 464 mg/dl). By 8 wk after transplantation, serum cholesterol in the EG-control mice was 462 and 684 mg/dl, whereas the mean serum cholesterol in the EO-treated mice was down to 131+24 mg/dl. Repopulation by the transplanted bone marrow cells was monitored at 5 wk in the peripheral blood leukocytes of EOcontrol and EO-treated mice. To document repopulation we used donor wild-type mice that expressed an altered version (Ly5.2) of the common leukocyte antigen, CD45. The CD45Ly5.2 antigen was identified by flow cytometry with a biotinylated monoclonal antibody and FITC-conjugated streptavidin. Because the apo E-deficient mice express the CD45Ly5.1 allele, the leukocytes from the EO-control mouse were not stained with the CD45Ly5.2 alloantigen-specific monoclonal antibody (Fig. 2,  left) . In contrast, the leukocytes of an EO-treated mouse expressed this wild-type donor cell alloantigen indicating repopulation by the donor bone marrow cells (Fig. 2, right) .
The serum lipoprotein phenotypes of the chow-fed mice were qualitatively analyzed by agarose gel electrophoresis and the gels were stained with Oil Fat 7B to reveal the lipoproteins (Fig. 3) marrow transplantation (Fig. 4) . characterized by a major HDL c able levels of VLDL and IDL chc in the EQ-treated mice was simila only a small increase in IDL an( the predominant cholesterol-contz homologous EQ-control mice dis and IDL cholesterol and reduce4 This phenotype was indistingui, yielded a 686-bp product only with wild-type apo E mRNA ( Fig. 5 B) .
8 wk after transplantation, both mutant and wild-type apo E mRNAs were present in the tissues of all mice, as seen by a single band of the predicted size using primers 2/3 (Fig. 5 A) . Wild-type apo E mRNAs were detected only in the tissues of wild-type and EQ-treated mice, as seen by the predicted bands -Wid using primers 1/3. Because wild-type apo E mRNA was deEOtb tected in the liver, spleen, and brain of the EO-treated mice 8 wk after irradiation, at least these three tissues had been repopulated by cells derived from the wild-type donor bone marrow.
Mice fed an atherogenic diet. Apo E-deficient mice fed an atherogenic diet containing 1.25% wt/wt cholesterol developed severe hypercholesterolemia within 2-3 wk (13) . To assess the effect of bone marrow transplantation on a more severe hypercholesterolemia phenotype, eight mice were put on a high fat diet 1 wk after bone marrow transplantation. These mice LDL HOL were monitored for their total serum cholesterol levels and examined visually for atherosclerotic lesion formation. Although serum cholesterol levels were similar between the EO-control- 20 30 40 HF and EO-treated-HF animals before bone marrow transplanta-)n number tion, significant differences in mean cholesterol levels between from wild-type, EO-control, and the two groups were apparent after 2 wk (Fig. 6) . From tions from other animals showed similar differences in lesion shable from that of nonbone formation between the two groups. marrow transplanted apo E-deficient mice.
To qualitatively monitor the expression of apo E in the liver, spleen, and brain of the transplanted mice, apo E mRNA was identified by reverse transcriptase-PCR. Piedrahita et al. (17) created the original mutant apo E gene by replacing a 131 base fragment of exon 3 plus a portion of intron 3 (an XhoI/BamHI fragment) with the neomycin phosphotransferase (neo) gene. To detect both the defective neo-apo E mRNA (generated from transcription by the promoter in the neo-containing plasmid) and the normal apo E mRNA, two sets of primers were used (Fig. 5 B) . The downstream primer (5'-CTGGCGATGCAT-GTCTTCCAC-3') was common for both mRNAs and bound near the 3' end of exon 4 (primer 3). The upstream primer for detection of both mutant and normal mRNAs (5'-TGGGCC-AGAGCACAGAGGAG-3') bound near the 5' end of exon 4 (primer 2). The other upstream primer for detection of normal mRNA (5 '-TCTGACCAGGTCCAGGAAGAG-3') bound the region in exon 3 replaced by the neo gene in the mutant mRNA (primer 1). Primers 2/3 yielded a 449-bp product with both mutant and wild-type apo E mRNAs, whereas primers 1/3 Discussion This study demonstrated that repopulation of chow-fed apo Edeficient mice with bone marrow cells from apo E-expressing wild-type mice reversed their hypercholesterolemia and qualitatively converted their lipoprotein phenotype to that of wild-type mice. Because complete repopulation of the peripheral blood leukocytes of the apo E-deficient mice occurred within 5 wk of transplantation, and because only the myeloid stem cells give rise to monocytes within the peripheral blood leukocytes that can eventually synthesize apo E ( 1, 6), the likely source of apo E in the EQ-treated mice was the transplanted wild-type bone marrow-derived macrophages.
In human bone marrow transplant recipients, blood macrophages are almost entirely of donor origin as early as 41 d after transplantation, and exhibit normal function (18). Furthermore, hepatic and alveolar macrophages originate from donor bone marrow cells (19) (20) (21) (22) (23) (24) (25) (26) The total amount of macrophage-derived apo E in the body is unknown. A study of apo E mRNA expression by rat Kupffer cells indicated that Kupffer cell-derived apo E mRNA is < 1% of the total apo E mRNA of hepatocytes (28) . In mice, Kupffer cells account for 20% of all macrophages in the body (29) .
If the synthesis of apo E by all macrophages is similar to that of Kupffer cells, total contribution by the entire macrophage population to circulating apo E should be < 5% of that of the hepatocytes. If so, the reduction in hypercholesterolemia seen in the EO-treated mice suggests that only small amounts of apo E were required for hepatic clearance of VLDL and IDL cholesterol. Furthermore, because serum levels of apo E in the E0-treated mice (estimated by Coomassie staining and Western blotting of SDS-PAGE-separated proteins) were undetectable and therefore probably < 10% of the circulating levels of wildtype mice, the nearly normal hepatic uptake of cholesterol seen in the EO-treated mice may not be dependent on apo E that circulates in association with lipoproteins. Recent evidence suggests that heparan sulfate proteoglycans and LRP in the space of Disse play a key role in remnant lipoprotein uptake by the liver (30) . If, as suggested by the reverse transcriptase-PCR data, the livers of the EG-treated mice contained apo E mRNA, locally produced apo E may be secreted by the Kupffer cells, promptly bound to cell surface proteoglycans, lipases, and/or phospholipids where it then becomes associated with cholesterol-rich lipoproteins that are immediately internalized by LRP for catabolism within hepatocytes. Thus, most of the hepatically derived apo E may remain in the space of Disse and not be present on circulating lipoproteins. It also is feasible that circulating lipoproteins containing apo E in the EO-treated mice are cleared very quickly by the liver, which could render the plasma apo E undetectable as well using standard methods. The degree of apo E synthesis within the liver and its utilization in the E0-treated mice are being investigated.
The reduction in HDL cholesterol seen in the apo E-defi- Figure 7 . En face color photographs of the dissected and Sudan IV-stained aortae of an EQ-control-HF mouse and an EQ-treated-HF mouse. The animals were killed 16 wk after bone marrow transplantation when they had been on the high fat diet for 15 wk. A shows the aortae of an EQcontrol-HF mouse on the left and an EQ-treated-HF mouse on the right. B and C are close-ups of the thoracic and abdominal regions, respectively, of the aortae shown in A. A visual comparison of the two aortae suggests a significant difference in the extent of lesion formation in the two groups of fat-fed animals. cient mice has been reported by other investigators (12, 13). The apparent increase in HDL cholesterol in our EO-treated mice to levels similar to those of wild-type mice implies that apo E may be required for normal metabolism of HDL cholesterol. However, the mechanism involved in this phenomenon is unknown. According to Zhang et al. (13) , despite similarities in apo AI levels in the plasma of wild-type and apo E-deficient mice, HDL cholesterol in the apo E-deficient mice is half that of the wild-type mice. This apparent difference may be attributed to utilization of apo Al for structural components of VLDL and IDL that could lead to a shortage of apo AI for assembly of HDL (13) . If so, it is plausible that more apo Al could have been available for HDL assembly in our EO-treated mice because of the sharp reduction in VLDL and IDL, and this resulted in higher HDL levels. Clearly, more studies are needed to understand the mechanism behind this observation.
The fourfold reduction in serum cholesterol in the EOtreated-HF mice compared to EO-control-HF animals clearly shows that wild-type bone marrow-containing cells capable of expressing apo E were effective in protecting apo E-deficient animals from the severe hypercholesterolemia caused by feeding an atherogenic diet. This protective effect was convincingly demonstrated by the reduced atherosclerotic lesion areas grossly observed in the aortae of the EO-treated mice compared to their control counterparts.
Although cholesterol levels of the animals in this study were monitored for only 8 wk after transplantation, the results suggest that permanent transfer of the apo E gene was accomplished with bone marrow transplantation and that this gene transfer can correct the severe hypercholesterolemia phenotype associated with apo E deficiency. Furthermore, the data suggest that bone marrow transplantation may permanently treat the hypercholesterolemia that leads to atherosclerosis and cardiovascular disease in apo E-deficient animals. A more quantitative study of the effect of this treatment on arterial lesion formation in apo E-deficient mice is being actively pursued.
